Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07780383). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 84 participants (ESTIMATED). Conditions: Alzheimer's Disease, Healthy Participants. Interventions: DRUG: BMS-986446. Primary outcome measures: Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion , Up to approximately 5 months; Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion , Up to approximately 5 months; Maximum observed concentration (Cmax) , Up to approximately 5 months; Time of maximum observed concentration (Tmax) , Up to approximately 5 months; Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) , Up to approximately 5 months; Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672)) , Up to approximately 5 months; AUC(INF) , Up to approximately 5 months; Half-life (T-HALF) , Up to approximately 5 months; Apparent total body clearance in SC administration (CLT/F) , Up to approximately 5 months; Total body clearance in IV infusion (CLT) , Up to approximately 5 months; Apparent volume of distribution of terminal phase in SC administration (Vz/F) , Up to approximately 5 months; Volume of distribution of terminal phase (VZ) , Up to approximately 5 months. Brief summary: The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration